secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001104659-25-046137
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma Q1 net loss $13.6M; YUPELRI sales up 6% to $58.3M
----------------------------------------------------------------------

- YUPELRI net sales of $58.3M recognized by Viatris, up 6% vs Q1 2024; Theravance's implied 35% share $20.4M.
- Net loss $13.6M vs $11.7M in Q1 2024; Non-GAAP net loss from ops $8.6M vs $4.5M.
- Revenue $15.4M entirely from Viatris collaboration, up 6% YoY.
- Cash $131M, no debt; reaffirming all financial guidance.
- CYPRESS study open label enrollment nearing completion, final patient expected by late summer; top-line data ~6 months later.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465925046137/0001104659-25-046137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465925046137/tm2514363d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-046137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer